(Q48678090)

14 February 2018

title

Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. (English)

1 reference

14 February 2018

main subject

heart failure

0 references

chronic heart failure

1 reference

3

1 reference

14 February 2018

Michele Gulizia

object named as

Michele Gulizia

10

0 references

Gianfranco Sinagra

object named as

Gianfranco Sinagra

15

0 references

author name string

Aneta Aleksova

1

1 reference

14 February 2018

Serge Masson

2

1 reference

14 February 2018

Donata Lucci

4

1 reference

14 February 2018

Renato Urso

5

1 reference

14 February 2018

Lidia Staszewsky

6

1 reference

14 February 2018

Stefano Ciaffoni

7

1 reference

14 February 2018

Giuseppe Cacciatore

8

1 reference

14 February 2018

Gianfranco Misuraca

9

1 reference

14 February 2018

Lucio Mos

11

1 reference

14 February 2018

Gianni Proietti

12

1 reference

14 February 2018

Calogero Minneci

13

1 reference

14 February 2018

Roberto Latini

14

1 reference

14 February 2018

on the behalf of the CandHeart Investigators

16

1 reference

14 February 2018

publication date

3 February 2012

1 reference

14 February 2018

Cardiovascular Drugs and Therapy

published in

1 reference

14 February 2018

volume

26

1 reference

14 February 2018

issue

6

1 reference

14 February 2018

page(s)

131-143

1 reference

14 February 2018

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Molecular mechanisms of myocardial remodeling. The role of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Aldosterone blockade in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

B-type natriuretic peptide-guided heart failure therapy: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

The placebo effect in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Albuminuria in chronic heart failure: prevalence and prognostic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6370-8

10.1007/S10557-012-6370-8

21 January 2018

Identifiers

DOI

1 reference

14 February 2018

1 reference

14 February 2018